Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease and other serious diseases, announced that data on its lead clinical compound, AKB-6548, will be presented at the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51(st) Congress being held in Amsterdam May 31 — June 3, 2014. AKB-6548 is a once-daily, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor in development for the treatment of anemia related to chronic kidney disease (CKD). Akebia Therapeutics Inc (NASDAQ:AKBA) weekly performance is 2.95%. On last trading day company shares ended up $28.62. Analysts mean target price for the company is $45.00. Akebia Therapeutics Inc (NASDAQ:AKBA) distance from 50-day simple moving average is 16.15%.
Atossa Genetics Inc (NASDAQ:ATOS) announced that Steven C. Quay, M.D., Ph.D., Chairman, CEO and President will be a featured presenter at the Life Science Innovation Northwest 2014 Exposition (LSINW), North America’s largest, fully-integrated Life Science Exposition, on Friday, June 20, 2014 from 1:15 to 1:35 pm PDT at the Washington State Convention Center, Seattle, WA. Atossa Genetics Inc (NASDAQ:ATOS) shares advanced 5.23% in last trading session and ended the day on $1.61. ATOS Gross Margin is 40.00% and its return on assets is -77.90%. Atossa Genetics Inc (NASDAQ:ATOS) quarterly performance is -8.52%.
Research analysts at Janney Montgomery Scott assumed coverage on shares of Foundation Medicine (NYSE:FMI) in a report released on Wednesday. The firm set a “neutral” rating on the stock.Foundation Medicine Inc (NASDAQ:FMI) shares moved up 6.93% in last trading session and was closed at $24.55, while trading in range of $22.90-$24.64. Foundation Medicine Inc (NASDAQ:FMI) year to date performance is 3.06%.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) have been given an average rating of “Buy” by the nine analysts that are currently covering the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) ended the last trading day at $12.67. Company weekly volatility is calculated as 5.20% and price to cash ratio as 3.58. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showed a positive weekly performance of 5.23%.
On May 30, 2014 Novadaq Technologies Inc. (NASDAQ:NVDQ) , the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, announced that management will present the Company’s corporate overview at three investor conferences in June. Novadaq Technologies Inc. (NASDAQ:NVDQ) weekly performance is -1.11%. On last trading day company shares ended up $16.01. Analysts mean target price for the company is $18.93. Novadaq Technologies Inc. (NASDAQ:NVDQ) distance from 50-day simple moving average is 1.58%.